Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IPSC
#3009
Century Therapeutics, Inc. Common Stock
2.3
2
+6.42%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+6.42%
Monthly Change
-13.43%
6 month change
+346.15%
Year Change
+256.92%
Previous Close
2.1
8
Open
2.3
2
Bid
Ask
Low
2.3
2
High
2.3
2
Volume
15
Markets
US Stock Market
Healthcare
IPSC
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
TD Cowen initiates Century Therapeutics stock rating at Buy
Oracle, Palantir among market cap stock movers on Monday
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics stock price target raised to $4 from $2 at Piper Sandler
Century Therapeutics stock price target lowered to $6.60 at Clear Street
Century Therapeutics secures $135 million in private placement
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
Century Therapeutics appoints two new board members
Century Therapeutics stock downgraded by Leerink Partners on lack of catalysts
Century Therapeutics unveils T1D therapy program with immune evasion tech